安徽黄山胶囊股份有限公司 关于开展票据池业务的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 安徽黄山胶囊股份有限公司（以下简称"公司"）于 2023 年 8 月 18 日召开 第五届董事会第三次会议和第五届监事会第三次会议，审议通过了《关于公司开 展票据池业务的议案》，为满足公司的发展需要、降低财务成本、提高资金使用 效率，同意公司在商业银行开展票据池业务，额度不超过 8000 万元，期限为自 董事会审议通过之日起 1 年，额度在上述业务期限内可滚动使用。本议案在公司 董事会审议权限范围内，无需提交股东大会审议。具体情况如下： 一、票据池业务情况 证券代码：002817 证券简称：黄山胶囊 公告编号：2023-024 1. 业务概述 票据池业务是指协议银行为满足企业客户对所持有的商业汇票进行统一管 理、统筹使用的需求，向企业提供的集票据托管和托收、票据质押池融资、票据 贴现、票据代理查询、业务统计等功能于一体的票据综合管理服务。 2. 合作银行 公司拟开展票据池业务的合作银行为国内资信较好的商业银行，具体合作银 行提请公司董事会授权公司管理层根据公司 ...

股票代码：002817 股票简称：黄山胶囊 编号：2023-001 投资者关系活动类 □特定对象调研 □分析师会议 别 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人 线上参与黄山胶囊 2022 年度网上业绩说明会的投资者 员姓名 时间 2023 年 05 月 10 日（星期三）下午 15:00-17:00 地点 "黄山胶囊投资者关系"微信小程序 董事、总经理：余超彪先生 上市公司接待人员 独立董事：沙风先生 姓名 副总经理：叶松林先生 副总经理：楚振华先生 财务总监：刘清科先生 副总经理、董事会秘书：张文政先生 1、问：现阶段来看，公司主要发展战略及重心是什么 答：尊敬的投资者您好！公司围绕"打造国内领先的医药 科技服务平台"这一长期目标。依托胶囊主营业务，深入 实施创新驱动发展战略，加大研发投入，加快设备更新和 投资者关系活动主 技术改造，持续提升生产车间智能化水平，进一步释放产 要内容介绍 能；加强技术合作与攻关，加大产品创新力度，着力提升 植物胶囊等新产品新工艺的研究，培育新的利润增长点。 继续深入推进产业结构布局优化，深化与战略客 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 143,226,804.73, representing a 41.37% increase compared to CNY 101,310,277.27 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was CNY 20,099,932.36, up 43.88% from CNY 13,969,880.23 year-on-year[5] - The net profit excluding non-recurring gains and losses was CNY 17,505,461.75, reflecting a significant increase of 78.84% compared to CNY 9,788,481.93 in the previous year[5] - The company's basic and diluted earnings per share both increased by 40.00%, reaching CNY 0.07 per share[5] - Total operating revenue for the current period reached ¥143,226,804.73, a significant increase of 41.4% compared to ¥101,310,277.27 in the previous period[32] - Net profit for the current period was ¥20,210,432.75, representing a 45.0% increase from ¥13,929,428.55 in the same period last year[33] - The company reported a total profit of ¥23,065,598.15, which is a 52.5% increase from ¥15,154,366.55 in the previous period[33] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to CNY 1,059,728,813.29, a 2.12% increase from CNY 1,037,692,058.04 at the end of the previous year[5] - The total equity attributable to the parent company reached ¥873,820,519.63, up from ¥853,758,112.73, indicating an increase of approximately 2.8%[30] - Total current assets amounted to ¥657,357,073.08, up from ¥618,271,712.89, reflecting a growth of approximately 6.3%[29] - Total liabilities increased slightly to ¥185,355,051.05 from ¥183,481,821.74, showing a growth of about 1%[30] Cash Flow - The net cash flow from operating activities decreased by 168.43%, amounting to -CNY 16,148,615.37, compared to CNY 23,600,068.31 in the same period last year[5] - Cash flow from operating activities showed a net outflow of ¥16,148,615.37, contrasting with a net inflow of ¥23,600,068.31 in the prior period[35] - The company reported a 135.32% increase in net cash flow from investing activities, amounting to CNY 17,693,720, mainly due to the redemption of financial products[22] - The company experienced a significant increase in cash inflow from investment activities, totaling ¥46,183,201.83, compared to a net outflow of -¥130,754,044.31 in the previous period[36] - The net increase in cash and cash equivalents was CNY 13,900,880, reflecting a growth of 127.47% compared to the previous year[25] - Cash and cash equivalents at the end of the period totaled ¥348,562,527.05, an increase from ¥234,839,284.78 at the end of the previous period[37] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,152[27] - The largest shareholder, Shandong Lutai Holdings, holds 29.99% of shares, totaling 89,699,541 shares[27] - The number of shares held by the top ten shareholders includes significant stakes from both state-owned and individual investors, with the top two shareholders holding a combined 38.05%[27] Accounts Receivable - Accounts receivable increased by 58.63%, totaling CNY 51,775,800, primarily due to increased sales and delayed collection[9] - Accounts receivable rose to ¥140,080,825.88 from ¥88,304,996.07, indicating an increase of about 58.6%[29] Research and Development - Research and development expenses increased to ¥4,868,433.54, up from ¥3,869,928.41 in the previous period, indicating a focus on innovation[32] Other Information - The company received government subsidies amounting to CNY 2,810,849.06 during the quarter, contributing to its financial performance[6] - The company has not disclosed any new product developments or market expansion strategies in the current report[28] - Other comprehensive income after tax was reported at -¥46,906.81, compared to -¥11,474.97 in the previous period[33]

Financial Performance - The company's operating revenue for 2022 was ¥428,318,791.71, representing a 12.75% increase compared to ¥379,891,008.70 in 2021[23] - The net profit attributable to shareholders for 2022 was ¥60,850,372.05, a 6.97% increase from ¥56,887,811.36 in 2021[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥51,050,352.05, up 5.69% from ¥48,301,265.66 in the previous year[23] - The total assets at the end of 2022 were ¥1,037,692,058.04, down 1.53% from ¥1,053,820,293.60 at the end of 2021[23] - The net assets attributable to shareholders at the end of 2022 were ¥853,758,112.73, an increase of 5.44% from ¥809,694,572.19 at the end of 2021[23] - The basic earnings per share for 2022 were ¥0.20, a 5.26% increase from ¥0.19 in 2021[23] - The diluted earnings per share for 2022 were also ¥0.20, reflecting the same increase of 5.26% from the previous year[23] - The weighted average return on equity for 2022 was 7.34%, slightly up from 7.25% in 2021[23] Cash Flow - The net cash flow from operating activities was ¥83,016,820.72, a decrease of 3.57% from ¥86,089,406.99 in 2021[23] - Operating cash inflow increased by 10.09% to ¥391,715,445.37, while operating cash outflow rose by 14.45% to ¥308,698,624.65[61] - Net cash flow from operating activities decreased by 3.57% to ¥83,016,820.72[61] - Investment cash inflow surged by 258.65% to ¥545,466,959.68, while investment cash outflow increased by 204.74% to ¥559,132,194.23[61] - Net cash flow from investment activities improved by 56.47% to -¥13,665,234.55[62] - Cash and cash equivalents decreased by 124.69% to -¥25,285,572.34, primarily due to reduced financing cash flow[62] Revenue Breakdown - The company's total revenue for Q1 2022 was approximately CNY 101.31 million, with a peak in Q4 2022 at CNY 127.14 million, indicating a quarterly fluctuation of 25.3%[27] - Net profit attributable to shareholders for Q2 2022 was CNY 17.55 million, while Q4 2022 saw a decline to CNY 12.75 million, reflecting a decrease of 27.5%[27] - The sales of gel capsules accounted for 79.17% of total revenue, with a revenue of ¥339,080,226.02, up 10.88% from ¥305,805,926.12 in 2021[50] - Domestic sales reached ¥397,971,632.29, making up 92.91% of total revenue, while international sales surged by 157.43% to ¥30,347,159.42, representing 7.09% of total revenue[50] Research and Development - Research and development investment amounted to 14.98 million yuan, with 8 patent applications filed, including 3 invention patents[47] - R&D investment rose by 11.47% to ¥14,980,970.94, accounting for 3.50% of operating revenue[59] - The company has initiated several new product development projects, including hydroxypropyl methylcellulose hollow capsules, aiming for annual sales of 4 billion pieces[58] - Research and development expenses rose by 11.47% to ¥14,980,970.94 in 2022, compared to ¥13,439,131.79 in 2021[58] Market Strategy - The pharmaceutical industry is transitioning towards high-quality development, with a focus on product innovation and international expansion as outlined in the "14th Five-Year Plan" for the pharmaceutical industry[33] - The company is enhancing brand promotion in the traditional Chinese medicine sector to adapt to market changes and maintain healthy growth[34] - The company aims to enhance its competitive advantage through continuous investment in technology research and development, aiming to become a leading pharmaceutical technology service platform in China[45] - The company plans to optimize its industrial structure and expand international market presence to overcome development bottlenecks[74] - The company is expanding its human resources management to address the potential mismatch between talent supply and business growth needs[77] Governance and Compliance - The company held three shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[81] - The company maintains independent operations from its controlling shareholder, ensuring no interference in decision-making[85] - The company has established a complete and independent financial accounting system, allowing for autonomous financial decision-making[87] - The company has established rules for related party transactions to ensure they follow market principles[89] - The company conducted a self-assessment of its governance structure, finding it compliant with relevant laws and regulations, with no major defects affecting operations[135] Shareholder Information - The company plans to distribute a cash dividend of ¥0.6 per 10 shares, totaling approximately ¥17,945,908.20 based on 299,098,170 shares[4] - The company reported a cash dividend of RMB 17,945,890.20 for the fiscal year, which represents 29.49% of the distributable profit of RMB 411,140,417.21[124] - The total number of shares increased from 213,641,550 to 299,098,170 after a capital reserve conversion, resulting in a 40.00% increase in total shares[180] - The largest shareholder, Shandong Lutai Holding Group, holds 29.99% of the shares, totaling 89,699,541 shares[187] Employee Management - The total number of employees at the end of the reporting period was 681, with 493 in production, 30 in sales, 81 in technical roles, 7 in finance, and 70 in administration[118] - The company implemented a performance-oriented salary system, enhancing employee motivation and retention through various incentive mechanisms[119] - The training completion rate for the year was 100%, with 429 frontline employees trained in SOP and professional knowledge, and 59 new employees receiving pre-job skills training[121] - The company has established a comprehensive training management system, combining internal and external training to enhance employee skills[121] Environmental and Social Responsibility - The company invested in supercritical CO2 heating and cooling systems and catalytic combustion systems, effectively reducing energy consumption and emissions[136] - The company donated 154,500 yuan to social welfare activities, including blood donation and support for disadvantaged employees[137] - The company emphasizes the importance of timely and accurate information disclosure to protect the rights of shareholders and creditors[134] Future Outlook - The company’s future outlook remains positive, with expectations of continued growth in revenue and market share[98] - The company has set a revenue target of 1 billion RMB for the next fiscal year, indicating a growth expectation of 25%[105] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[105] - The company aims to strengthen its competitive position in the industry through potential mergers and acquisitions, although no specific targets were mentioned[98]

证券代码：002817 证券简称：黄山胶囊 公告编号：2023-016 安徽黄山胶囊股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、业绩说明会内容 安徽黄山胶囊股份有限公司（以下简称"公司"）已于2023年4月28日在巨 潮资讯网（http://www.cninfo.com.cn/）上披露了《黄山胶囊2022年年度报告》。 为便于广大投资者进一步了解公司2022年年度经营情况，加强公司与投资者的沟 通互动，定于2023年05月10日（星期三）下午15:00至17:00时在"黄山胶囊投资 者关系"小程序举行2022年度网上业绩说明会。 二、投资者参会方式 本次年度业绩说明会将通过约调研平台采用网络远程方式举行，投资者可通 过以下方式参与本次业绩说明会： 参与方式一：在微信小程序中搜索"黄山胶囊投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"黄山胶囊投资者关系"小程序，即可参与交流。 三、参会人员 出席本次网上说明会的人员有：董事、总经理余超彪先生，独立董事沙风先 生，副总 ...

证券代码：002817 证券简称：黄山胶囊 安徽黄山胶囊股份有限公司投资者关系活动记录表 编号：2019-001 | --- | --- | --- | |-------------------------|-----------------------------|------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 ■业绩说明会 | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | 参与单位名称及 人员姓名 | 投资者 | | | | | | | 时间 | 2019 年 5 月 6 日 | 15:00-17:00 | | 地点 | " 全景•路演天下"（ | http://rs.p5w.net ） | | 上市公司接待人 | 董事长 余春明 | | | 员姓名 | 总经理 余超彪 | | | | 董事会秘书 项先理 | | | | 财务负责人 汪红时 | | | | 独立董事 曲凯 | | | | 保荐代表人 高震 | ...

Group 1: Company Overview and Strategy - Anhui Huangshan Capsule Co., Ltd. aims to become a leading pharmaceutical technology service platform in China [1][4] - The company focuses on scientific budgeting and refined management to align expenses with business development [4] Group 2: Product Information - The main product, gelatin hollow capsules, is primarily used for drugs sensitive to light and moisture, enhancing bioavailability compared to tablets [5] - The market for gelatin hollow capsules remains dominant, with HPMC plant-based capsules as a supplementary option due to higher costs and regulatory restrictions [4][5] Group 3: Financial Performance and Market Position - The company reported a significant portion of revenue from gelatin hollow capsules, indicating a concentrated revenue stream [6][7] - The company has established a good reputation among domestic pharmaceutical and health food enterprises, maintaining a stable customer base [7] Group 4: Overseas Market Expansion - The company has made progress in expanding into the North American market, including the establishment of a subsidiary in the U.S. and exporting five batches of capsules [7][9] - Future overseas sales are expected to grow, driven by increased demand due to the COVID-19 pandemic [9][13] Group 5: Risks and Challenges - Potential risks in overseas expansion include rising shipping costs, exchange rate fluctuations, and instability in overseas client operations due to the pandemic [6][13] - The company is aware of the challenges posed by the international political environment and is prepared to address them [13] Group 6: Research and Development - The company plans to increase investment in R&D, focusing on plant-based capsules and enteric-coated gelatin capsules to diversify its product offerings [8][10] - Current production capacity is projected to exceed 40 billion capsules, supported by the completion of a digital workshop [11]

Group 1: Financial Performance and Investment - The company has seen a 43.76% increase in R&D investment in 2021 compared to the previous year, reflecting its ongoing commitment to research and development [1][2] - The company has not engaged in direct financing since its IPO, relying instead on loans for specific projects, such as the "Hollow Capsule Intelligent Manufacturing New Model" project [1] - The company maintains a low level of interest-bearing debt, benefiting from favorable bank loan rates [1] Group 2: Production Capacity and Market Position - Anhui Huangshan Capsule Co., Ltd. is one of the largest manufacturers of pharmaceutical hollow capsules, with an annual production capacity exceeding 40 billion capsules [2] - The company utilizes advanced intelligent manufacturing technology, allowing for the production of various specifications and customized services [2] Group 3: Shareholder Concerns and Market Performance - The company's stock price has declined significantly from a peak of 83 yuan to below 8 yuan, raising concerns among shareholders about the company's future [2] - The company is focused on steady operations and aims to create sustainable long-term returns for investors despite market fluctuations [2]

Financial Performance - The company's revenue for Q3 2022 was ¥93,656,298.81, representing a 13.10% increase year-over-year[5] - Net profit attributable to shareholders for the same period was ¥16,583,398.01, up by 3.32% compared to the previous year[5] - Total operating revenue for the third quarter of 2022 was CNY 301,178,173.56, an increase of 8.3% compared to CNY 278,105,057.36 in the same period last year[39] - Net profit for the third quarter reached CNY 48,220,190.73, representing a 16.5% increase from CNY 41,406,384.94 in the previous year[40] - Earnings per share (EPS) for the quarter was CNY 0.16, compared to CNY 0.14 in the same quarter last year, indicating a growth of 14.3%[40] - The total equity attributable to shareholders of the parent company was CNY 840,944,224.34, up from CNY 809,694,572.19, reflecting a growth of 3.9%[39] - The total comprehensive income for the quarter was CNY 48,522,337.05, an increase from CNY 41,496,818.78, representing a growth of 17.3%[40] Cash Flow - The operating cash flow net amount for the year-to-date period reached ¥67,058,100.52, showing a significant increase of 111.46%[5] - The net cash flow from operating activities increased by ¥35,345,400, a growth of 111.46%, attributed to higher cash receipts from sales[29] - The net cash flow from operating activities for the period was ¥67,058,100.52, an increase of 111.1% compared to ¥31,712,693.40 in the previous period[41] - Total cash inflow from investment activities was ¥453,876,802.98, significantly higher than ¥5,458,760.93 in the previous period[41] - The net cash flow from investment activities was -¥246,780,048.91, worsening from -¥63,490,876.00 in the previous period[41] - Cash flow from financing activities resulted in a net outflow of -¥22,234,805.05, compared to a net inflow of ¥39,251,572.00 in the previous period[42] - The total cash and cash equivalents at the end of the period stood at ¥142,238,131.71, down from ¥248,958,363.80 at the end of the previous period[42] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,093,508,453.78, reflecting a 3.77% increase from the end of the previous year[5] - The total liabilities increased to CNY 252,101,974.12 from CNY 243,844,826.99, marking a rise of 3.1%[39] - The company’s non-current liabilities decreased to CNY 93,153,737.79 from CNY 97,947,796.63, a decline of 5.0%[39] - The company’s non-current assets total RMB 422,465,387.55 as of September 30, 2022, slightly up from RMB 414,167,687.10 at the beginning of the year[36] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,622[31] - The largest shareholder, Yu Chunming, holds 38.05% of shares, totaling 113,802,815 shares, with 37,020,000 shares pledged[31] Investments and Expenses - The company reported a 116.08% increase in trading financial assets, amounting to ¥75,617,300, primarily due to investments in bank wealth management products[9] - Research and development expenses for the quarter were CNY 10,418,005.92, slightly down from CNY 11,284,663.73, indicating a decrease of 7.7%[39] - The company reported a financial income of CNY 4,837,532.59, compared to CNY 5,366,642.46 in the previous year, showing a decline of 9.9%[39] Inventory and Receivables - The company’s inventory as of September 30, 2022, is RMB 115,712,327.43, up from RMB 90,742,292.83 at the beginning of the year[36] - The company reported accounts receivable of RMB 103,197,011.65 as of September 30, 2022, an increase from RMB 80,999,747.90 at the beginning of the year[36]

Group 1: Event Details - Anhui Huangshan Capsule Co., Ltd. will participate in the "2022 Anhui Listed Companies Investor Collective Reception Day" [2] - The event will be held online on September 7, 2022, from 16:00 to 17:30 [2] - Investors can join via the "Panorama Roadshow" website, WeChat public account, or the Panorama Roadshow APP [2] Group 2: Communication Objectives - Company executives will discuss the 2022 semi-annual report, including company performance, governance, development strategy, operational status, and sustainable development [2] - The event aims to enhance interaction and communication with investors [2] Group 3: Assurance of Information - The company and its board guarantee the announcement's content is true, accurate, and complete, with no false records or significant omissions [2]